Author:
Wang Li,Han Chaonan,Cai Chenlei,Wu Jing,Chen Jianing,Su Chunxia
Reference47 articles.
1. Cancer treatment and survivorship statistics, 2019;Miller;CA A Cancer J. Clin.,2019
2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019
3. Five-year outcomes with Pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50;Reck;J. Clin. Oncol.,2021
4. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer;Gadgeel;J. Clin. Oncol.,2020
5. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study;Novello;J. Clin. Oncol.,2023